Altough disappointed by the preclinical GBM result, do you think this makes sense in that GBM is a primary brain cancer while most cancer in the brain is metastatic from another region of the body. The theory is that with with primarys' leronlimab, might have more value as a supplement to chemo--which is usually economical and generic--while reducing and/or preventing mets that usually cause patient mortality (with the exception of GBM).